. Inca, Les cancers en France en 2018 : l'essentiel des faits et chiffres (édition 2019)| Institut National Du Cancer

F. Barlesi, J. Mazieres, J. Merlio, D. Debieuvre, J. Mosser et al., Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). The Lancet, avr, vol.387, pp.1415-1441, 2016.

H. Denis, C. Davoine, E. Bermudez, G. Grosjean, M. Schwager et al., Les immunothérapies spécifiques dans le traitement des cancers, Bull Cancer (Paris). janv, vol.106, issue.1, pp.37-47, 2019.

C. Hayden and E. , Antibody alarm call rouses immune response to cancer, Nature. juin, vol.486, issue.7401, pp.16-16, 2012.

J. Brahmer, K. L. Reckamp, P. Baas, L. Crinò, W. Eberhardt et al., Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med. 9 juill, vol.373, issue.2, pp.123-158, 2015.

H. Borghaei, L. Paz-ares, L. Horn, D. R. Spigel, M. Steins et al., Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1666, 2015.

R. S. Herbst, P. Baas, D. Kim, E. Felip, J. L. Pérez-gracia et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, The Lancet. avr, vol.387, pp.1540-50, 2016.

M. Reck, D. Rodríguez-abreu, A. G. Robinson, R. Hui, T. Cs?szi et al., Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.375, pp.1823-1856, 2016.

A. Rittmeyer, F. Barlesi, D. Waterkamp, K. Park, F. Ciardiello et al., Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, openlabel, multicentre randomised controlled trial. The Lancet, vol.389, pp.255-65, 2017.

S. J. Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami et al., Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC, N Engl J Med. 13 déc, vol.379, issue.24, pp.2342-50, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02284390

S. Iivanainen and J. P. Koivunen, Early PD-1 Therapy Discontinuation in Responding Metastatic Cancer Patients, Oncology, vol.96, issue.3, pp.125-156, 2019.

M. Tachihara, S. Negoro, T. Inoue, M. Tamiya, Y. Akazawa et al., Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316). BMC Cancer, vol.18

B. Ricciuti, C. Genova, M. Bassanelli, D. Giglio, A. Brambilla et al., Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression. Clin Lung Cancer, 2019.

D. Sur,

S. Champiat, L. Dercle, S. Ammari, C. Massard, A. Hollebecque et al., Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1, Clin Cancer Res. 15 avr, vol.23, issue.8, pp.1920-1928, 2017.

L. Gandhi, D. Rodríguez-abreu, S. Gadgeel, E. E. Felip, E. et al., Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, N Engl J Med. 31 mai, vol.378, issue.22, pp.2078-92, 2018.

M. A. Socinski, R. M. Jotte, F. Cappuzzo, F. Orlandi, D. Stroyakovskiy et al., Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC, N Engl J Med. 14 juin, vol.378, issue.24, pp.2288-301, 2018.

D. T. Le, J. N. Durham, K. N. Smith, H. Wang, B. R. Bartlett et al., Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science. 28 juill, vol.357, issue.6349, pp.409-422, 2017.

O. Abdel-rahman, Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis, Crit Rev Oncol Hematol. mai, vol.101, pp.75-85, 2016.

F. Passiglia, G. Bronte, V. Bazan, C. Natoli, S. Rizzo et al., PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis, Oncotarget, vol.12, issue.2016

N. Mcgranahan and C. Swanton, Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future, Cell. févr, vol.168, issue.4, pp.613-641, 2017.

M. D. Hellmann, T. Ciuleanu, A. Pluzanski, J. S. Lee, G. A. Otterson et al., Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden, N Engl J Med. 31 mai, vol.378, issue.22, pp.2093-104, 2018.

J. Tanizaki, K. Haratani, H. Hayashi, Y. Chiba, Y. Nakamura et al., Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab, J Thorac Oncol. janv, vol.13, issue.1, pp.97-105, 2018.

L. Mezquita, E. Auclin, R. Ferrara, M. Charrier, J. Remon et al., Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer, JAMA Oncol. 1 mars, vol.4, issue.3, p.351, 2018.

S. Teraoka, D. Fujimoto, T. Morimoto, H. Kawachi, M. Ito et al., Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study, J Thorac Oncol. déc, vol.12, issue.12, pp.1798-805, 2017.

M. A. Postow, R. Sidlow, and M. D. Hellmann, Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. Longo DL, éditeur, N Engl J Med. 11 janv, vol.378, issue.2, pp.158-68, 2018.

S. A. Khan, S. L. Pruitt, L. Xuan, and D. E. Gerber, Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options, JAMA Oncol, vol.2, issue.11, p.1507, 2016.

, Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1 (AcSé) ClinicalTrials.gov Identifier, p.2034981

L. Beer, Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer, Clin Nucl Med, pp.447535-543, 2019.

L. Horn, D. R. Spigel, E. E. Vokes, E. Holgado, N. Ready et al., Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057), J Clin Oncol. 10 déc, vol.35, issue.35, pp.3924-3957, 2017.

S. J. Antonia, H. Borghaei, S. S. Ramalingam, L. Horn, D. Castro-carpeño et al., Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis, Lancet Oncol

D. Sur,

D. Planchard, S. Popat, K. Kerr, S. Novello, E. F. Smit et al., Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up ?, Ann Oncol, vol.29, issue.Supplement_4, pp.192-237, 2018.

T. Fulop, A. Larbi, R. Kotb, and G. Pawelec, Immunology of Aging and Cancer Development, Extermann M, éditeur. Interdisciplinary Topics in Gerontology, 2013.

F. Casaluce, A. Sgambato, P. Maione, A. Spagnuolo, and C. Gridelli, Lung cancer, elderly and immune checkpoint inhibitors, J Thorac Dis. mai, vol.10, issue.S13, pp.1474-81, 2018.

E. Muchnik, K. P. Loh, M. Strawderman, A. Magnuson, S. G. Mohile et al., Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer, J Am Geriatr Soc. mai, vol.67, issue.5, pp.905-917, 2019.

M. Bersanelli, M. Brighenti, S. Buti, S. Barni, and F. Petrelli, Patient performance status and cancer immunotherapy efficacy: a meta-analysis, Med Oncol, vol.35, issue.10, 2018.

J. Mazières, A. Drilon, A. Lusque, L. Mhanna, A. B. Cortot et al., Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry, Ann Oncol

D. Sur,

K. C. Arbour, L. Mezquita, N. Long, H. Rizvi, E. Auclin et al., Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With NonSmall-Cell Lung Cancer, J Clin Oncol, vol.36, issue.28, pp.2872-2880, 2018.

T. Hakozaki, Y. Okuma, M. Omori, and Y. Hosomi, Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer, Oncol Lett, vol.8, issue.2019

D. Sur,

B. Routy, L. Chatelier, E. Derosa, L. Duong, C. Alou et al., Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors, Science. 5 janv, vol.359, issue.6371, pp.91-98, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01727917

F. Huemer, G. Rinnerthaler, T. Westphal, H. Hackl, G. Hutarew et al., Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous nonsmall cell lung cancer, Oncotarget, vol.27, issue.2018

N. Bhalla, R. Brooker, and M. Brada, Combining immunotherapy and radiotherapy in lung cancer, J Thorac Dis. mai, vol.10, issue.S13, pp.1447-60, 2018.

E. E. Vokes, N. Ready, E. Felip, L. Horn, M. A. Burgio et al., Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases, Ann Oncol. 1 avr, vol.29, issue.4, pp.959-65, 2018.

H. Watanabe, T. Kubo, K. Ninomiya, K. Kudo, D. Minami et al., The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer, Jpn J Clin Oncol

D. Sur,

M. Tazdait, L. Mezquita, J. Lahmar, R. Ferrara, F. Bidault et al., Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria, Eur J Cancer. janv, vol.88, pp.38-47, 2018.

G. Ritchie, H. Gasper, J. Man, S. Lord, I. Marschner et al., Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis, JAMA Oncol. 1 avr, vol.4, issue.4, p.522, 2018.

, Cancer bronchique non à petites cellules -Référentiels